Modality
Bispecific Ab
MOA
BTKi
Target
SOS1
Pathway
Innate Imm
PSPBladder CaThymoma
Development Pipeline
Preclinical
Jul 2024
→ Apr 2028
PreclinicalCurrent
NCT03091800
835 pts·PSP
2024-07→2028-04·Recruiting
835 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-152.0y awayInterim· PSP
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Preclinical
Recruit…
Catalysts
Interim
2028-04-15 · 2.0y away
PSP
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03091800 | Preclinical | PSP | Recruiting | 835 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 |